Table 2. Summary of treatment-related... | American Society of Hematology

Table 2.

Summary of treatment-related adverse events occuring in more than 10% of patients

	Weeks on/off treatment by dosage and worst grade CTC, no. patients (no. events)
Adverse event	4/2 wk, 50 mg, CTC 1-2	4/2 wk, 50 mg, CTC 3-4	4/2 wk, 75 mg, CTC 1-2	4/2 wk, 75 mg, CTC 3-4	4/1 wk, 50 mg, CTC 1-2	4/1 wk, 50 mg, CTC 1-2
CTC, worst grade	1-2	3-4	1-2	3-4	1-2	3-4
Any events	3 (3)	0	1 (3)	1 (4)	5 (16)	0
Nausea	1 (1)	0	1 (1)	0	3 (5)	0
Fatigue	1 (1)	0	0	1 (2)	2 (2)	0
Jaundice	1 (1)	0	0	0	2 (2)	0
Lipase increase	0	0	0	1 (2)	1 (1)	0
Diarrhea	0	0	1 (1)	0	1 (1)	0
Vomiting	0	0	1 (1)	0	1 (1)	0
Constipation	0	0	0	0	2 (2)	0
Headache	0	0	0	0	2 (2)	0

	Weeks on/off treatment by dosage and worst grade CTC, no. patients (no. events)
Adverse event	4/2 wk, 50 mg, CTC 1-2	4/2 wk, 50 mg, CTC 3-4	4/2 wk, 75 mg, CTC 1-2	4/2 wk, 75 mg, CTC 3-4	4/1 wk, 50 mg, CTC 1-2	4/1 wk, 50 mg, CTC 1-2
CTC, worst grade	1-2	3-4	1-2	3-4	1-2	3-4
Any events	3 (3)	0	1 (3)	1 (4)	5 (16)	0
Nausea	1 (1)	0	1 (1)	0	3 (5)	0
Fatigue	1 (1)	0	0	1 (2)	2 (2)	0
Jaundice	1 (1)	0	0	0	2 (2)	0
Lipase increase	0	0	0	1 (2)	1 (1)	0
Diarrhea	0	0	1 (1)	0	1 (1)	0
Vomiting	0	0	1 (1)	0	1 (1)	0
Constipation	0	0	0	0	2 (2)	0
Headache	0	0	0	0	2 (2)	0